Effect of Rosuvastatin on plasma levels of asymmetric dimethylarginine in patients with hypercholesterolemia

American Journal of Cardiology

Volumn 94, Issue 2, 2004, Pages 157-161

  Lu, Tse Min ^b   Ding, Yu An ^a   Leu, Hsin Bang ^b   Yin, Wei Hsian ^b   Sheu, Wayne Huey Herng ^b   Chu, Kai Min ^b  

^a TAIPEI VETERANS GENERAL HOSPITAL   (Taiwan)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

C REACTIVE PROTEIN; HOMOCYSTEINE; N(G),N(G) DIMETHYLARGININE; ROSUVASTATIN;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORRELATION ANALYSIS; DISEASE ASSOCIATION; DRUG BLOOD LEVEL; DRUG EFFECT; FEMALE; HUMAN; HYPERCHOLESTEROLEMIA; MALE; OXIDATIVE STRESS; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; VASODILATATION;

AGED; ARGININE; CHOLESTEROL, HDL; CHOLESTEROL, LDL; DOUBLE-BLIND METHOD; ENDOTHELIUM, VASCULAR; FEMALE; FLUOROBENZENES; HOMOCYSTEINE; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; HYPERCHOLESTEROLEMIA; MALE; MIDDLE AGED; PYRIMIDINES; SULFONAMIDES; VASODILATION;

EID: 3142606890     PISSN: 00029149     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.amjcard.2004.03.052     Document Type: Article

References (27)

1. Leiper J., Vallance P. Biological significance of endogenous methylarginines that inhibit nitric oxide synthases. Cardiovasc Res. 43:1999;542-548
2. Miyazaki H., Matsuoka H., Cooke J.P., Usui M., Ueda S., Okuda S., Imaizumi T. Endogenous nitric oxide synthase inhibitor a novel marker of atherosclerosis. Circulation. 99:1999;1141-1146
3. Böger R.H., Bode-Böger S.M., Szuba A., Tsao P.S., Chan J.R., Tangphao O., Blaschke T.F., Cooke J.P. Asymmetric dimethylarginine (ADMA) a novel risk factor for endothelial dysfunction: its role in hypercholesterolemia. Circulation. 98:1998;1842-1847
4. Surdacki A., Nowichi M., Sandmann J., Tsikas D., Böger R.H., Bode-Böger S.M., Kruszelnicka-Kwiatkowska O., Kokot F., Dubiel J.S., Frölich J.C. Reduced urinary excretion of nitric oxide metabolites and increased plasma levels of asymmetric dimethylarginine in men with essential hypertension. J Cardiovasc Pharmacol. 33:1999;652-658
5. Abbasi F., Asagmi T., Cooke J.P., Lamendala C., McLaughlin T., Reaven G.M., Stühlinger M.C., Tsao P.S. Plasma concentrations of asymmetric dimethylarginine are increased in patients with type 2 diabetes mellitus. Am J Cardiol. 88:2001;1201-1203
6. Stühlinger M.C., Abbasi F., Chu J.W., Lamendola C., McLaughlin T.L., Cooke J.P., Reaven G.M., Tsao P.S. Relationship between insulin resistance and an endogenous nitric oxide synthase inhibitor. JAMA. 287:2002;1420-1426
7. Zoccali C., Bode-Böger S.M., Mallamaci F., Benedetto F.A., Tripepi G., Malatina L.S., Cataliotti A., Bellanuova I., Ferno I., Frölich J.C., Böger R.H. Plasma concentrations of asymmetrical dimethylarginine and mortality in patients with end-stage renal disease a prospective study. Lancet. 358:2001;2113-2117
8. Valkonen V.P., Pälvä H., Salonen J.T., Lakka T.A., Lehtimäki T., Laakso J., Laaksonen R. Risk of acute coronary events and serum concentration of asymmetrical dimethylarginine. Lancet. 358:2001;2127-2128
9. Lu T.M., Ding Y.A., Charng M.J., Lin S.J. Asymmetrical dimethylarginine a novel risk factor for coronary artery disease. Clin Cardiol. 26:2003;458-464
10. Lu T.M., Ding Y.A., Lin S.J., Lee W.S., Tai H.C. Plasma levels of asymmetrical dimethylarginine and adverse cardiovascular events after percutaneous coronary intervention. Eur Heart J. 24:2003;1912-1919
11. Ito A., Tsao P.S., Adimoolam S., Kimoto M., Ogawa T., Cooke J.P. Novel mechanism for endothelial dysfunction dysregulation of dimethylarginine dimethylaminohydrolase. Circulation. 99:1999;3092-3095
12. Böger R.H., Syndow K., Borlak J., Tuhm T., Lenzen H., Schubert B., Tsikas D., Bode-Böger S.M. LDL cholesterol upregulates synthesis of asymmetrical dimethylarginine in human endothelial cells involvement of S-adenosylmethionine-dependent methyltransferases. Circ Res. 87:2000;99-105
13. Böger R.H., Bode-Böger S.M., Tsao P.S., Lin P.S., Chan J.R., Cooke J.P. An endogenous inhibitor of nitric oxide synthase regulates endothelial adhesiveness for monocytes. J Am Coll Cardiol. 36:2000;2287-2295
14. Olsson A.G., Pears J., McKellar J., Mizan J., Raza A. Effect of rosuvastatin on low-density lipoprotein cholesterol in patients with hypercholesterolemia. Am J Cardiol. 88:2001;504-508
15. Jones S.P., Gibson M.F., Rimmer D.M., Gibson T.M., Sharp B.R., Lefer D.J. Direct vascular and cardioprotective effects of rosuvastatin, a new HMG-CoA reductase inhibitor. J Am Coll Cardiol. 40:2002;1172-1178
16. Laufs U., La Fata V., Plutzky J., Liao J. Upregulation of endothelial nitric oxide synthase by HMG-CoA reductase inhibitors. Circulation. 97:1998;1129-1135
17. Shishehbor M.H., Brennan M.L., Aviles R.J., Fu X., Penn M.S., Sprecher D.L., Hazen S.L. Statins promote potent systemic antioxidant effects through specific inflammatory pathways. Circulation. 108:2003;426-431
18. Vallance P., Leone A., Calver A., Collier J., Moncada S. Accumulation of an endogenous inhibitor of nitric oxide synthesis in chronic renal failure. Lancet. 339:1992;572-575
19. 2 isoprostanes in hypercholesterolemia. Circulation. 98:1998;2822-2828
20. Kanami P.M., Sinkey C.A., Browning R.L., Allaman M., Knapp H.R., Haynes W.G. Role of oxidant stress in experimental dysfunction produced by experimental hyperhomocyst(e)inemia in humans. Circulation. 100:1999;1161-1168
21. Lin K.Y., Ito A., Asagami T., Tsao P.S., Adimoolam S., Kimoto M., Tsuji H., Reaven G.M., Cooke J.P. Impaired nitric oxide synthase pathway in diabetes mellitus role of asymmetric dimethylarginine and dimethylarginine dimethylaminohydrolase. Circulation. 106:2002;987-992
22. Böger R.H., Bode-Böger S.M., Mügge A., Kienke S., Brandes R., Dwenger A., Frohlich J.C. Supplementation of hypercholesterolemic rabbits with L-arginine reduces the vascular release of superoxide anions and restores NO production. Atherosclerosis. 117:1995;273-284
23. Sydow K., Schwedhelm E., Arakawa N., Bode-Böger S.M., Tsikas D., Hornig B., Frölich J.C., Böger R.H. ADMA and oxidative stress are responsible for endothelial dysfunction in hyperhomocysteinemia effects of L-arginine and B vitamins. Cardiovasc Res. 57:2003;244-252
24. Stühlinger M.C., Oka R.K., Graf E.E., Schmölzer I., Upson B.M., Kapoor O., Szuba A., Malinow R., Wascher T.C., Pachinger O., Cooke J.P. Endothelial dysfunction induced by hyperhomocyst(e)inemia role of asymmetric dimethylarginine. Circulation. 108:2003;933-938
25. Giral P., Bruckert E., Jacob N., Chapman M.J., Foglietti M.J., Turpin G. Homocysteine and lipid-lowering agents a comparison between atorvastatin and fenofibrate in patients with mixed hyperlipidemia. Atherosclerosis. 154:2001;421-427
26. Päivä H., Laakso J., Lehtimäki T., Isomustajärvi M., Ruokonen I., Laaksonen R. Effect of high-dose statin treatment on plasma concentrations of endogenous nitric oxide synthase inhibitors. J Cardiovasc Pharmacol. 41:2003;219-222
27. Eid H.M., Eritsland J., Larsen J., Arnesen H., Seljeflot I. Increased levels of asymmetrical dimethylarginine in populations at risk for atherosclerosis disease. Effects of pravastatin. Atherosclerosis. 166:2003;279-284